Ikena Oncology to Participate in September 2023 Investor Conferences
September 05 2023 - 8:00AM
Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted
oncology company forging new territory in patient-directed cancer
treatment, today announced that management will participate in two
upcoming investor conferences in New York, NY.
Details are as follows:
Morgan Stanley 21st Annual Global Healthcare Conference,
September 11-13, 2023One-on-One Investor Meetings
September 11, 2023Fireside Chat: Monday, September 11, 2023, at
3:35pm ETWebcast Link
H.C. Wainwright 25th Annual Global Investment
Conference, September 11-13, 2023One-on-One Investor
Meetings September 13, 2023
The fireside chat webcast will be available on the Company’s
Events & Presentations page on their website at
www.ikenaoncology.com. The webcast will be archived for a period of
90 days following the conclusion of the live event.
About Ikena OncologyIkena Oncology® is focused
on developing differentiated therapies for patients in need that
target nodes of cancer growth, spread, and therapeutic resistance
in the Hippo and RAS onco-signaling network. The Company’s lead
targeted oncology program, IK-930, is a TEAD1 selective Hippo
pathway inhibitor, a known tumor suppressor pathway that also
drives resistance to multiple targeted therapies. The Company’s
additional research spans other targets in the Hippo pathway as
well as the RAS signaling pathway, including developing IK-595, a
novel MEK-RAF inhibitor. Additionally, IK-175, an AHR antagonist,
is being developed in collaboration with Bristol Myers Squibb.
Ikena aims to utilize their depth of institutional knowledge and
breadth of tools to efficiently develop the right drug using the
right modality for the right patient. To learn more, visit
www.ikenaoncology.com or follow us on Twitter and LinkedIn.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, as amended,
including, without limitation, implied and express statements
regarding: projected cash runway; the anticipated use of proceeds
from the underwritten registered offering and Pionyr acquisition,
the timing and advancement of our targeted oncology programs,
including the timing of updates; our expectations regarding the
therapeutic benefit of our targeted oncology programs; our ability
to efficiently discover and develop product candidates; our ability
to obtain and maintain regulatory approval of our product
candidates; the implementation of our business model, expectations
with respect to cash runway, and strategic plans for our business
and product candidates. The words “may,” “will,” “could,” “would,”
“should,” “expect,” “plan,” “anticipate,” “intend,” “believe,”
“estimate,” “predict,” “project,” “potential,” “continue,” “target”
and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Any forward-looking statements in this
press release are based on management’s current expectations and
beliefs and are subject to a number of risks, uncertainties and
important factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, those risks and uncertainties related to the timing and
advancement of our targeted oncology programs; our expectations
regarding the therapeutic benefit of our targeted oncology
programs; our ability to efficiently discover and develop product
candidates; the implementation of our business model, and strategic
plans for our business and product candidates, the sufficiency of
the Company’s capital resources to fund operating expenses and
capital expenditure requirements and the period in which such
resources are expected to be available, and other factors discussed
in the “Risk Factors” section of Ikena’s Quarterly Report on Form
10-Q for the quarter ended June 30, 2023, which is on file with the
SEC, as updated by any subsequent SEC filings. We caution you not
to place undue reliance on any forward-looking statements, which
speak only as of the date they are made. We disclaim any obligation
to publicly update or revise any such statements to reflect any
change in expectations or in events, conditions or circumstances on
which any such statements may be based, or that may affect the
likelihood that actual results will differ from those set forth in
the forward-looking statements. Any forward-looking statements
contained in this press release represent our views only as of the
date hereof and should not be relied upon as representing its views
as of any subsequent date. We explicitly disclaim any obligation to
update any forward-looking statements.Investor
Contact:Rebecca CohenIkena
Oncologyrcohen@ikenaoncology.com
Media Contact:Luke ShiploLifeSci
Communicationslshiplo@lifescicomms.com
Ikena Oncology (NASDAQ:IKNA)
Historical Stock Chart
From May 2024 to Jun 2024
Ikena Oncology (NASDAQ:IKNA)
Historical Stock Chart
From Jun 2023 to Jun 2024